Eloxx

Publication titled “A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer” published in Cancer Research Communications Results suggest that MYC…

Globally renowned Alport syndrome experts will provide key insights Eloxx recently announced achievement of remission in one patient in its Phase 2 Alport syndrome clinical study and decision to advance into a pivotal trial in Alport…

ELX-02 trial results demonstrated clinically relevant improvement in percent predicted forced expiratory volume (ppFEV1) based on final data assessment; initial topline results were previously reported in September 2022…

Topline results to include biopsy results for the Phase 2…

ZKN-013 in development for treatment of recessive dystrophic…